Education
About Us
Working with TipRanks
Follow Us
Insmed (INSM)
:INSM
INSM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$60.40 - $149.08
Previous CloseN/A
Volume462.72K
Average Volume (3M)2.75M
Market Cap
$30.60B
Enterprise Value$17.94B
Total Cash (Recent Filing)$1.86B
Total Debt (Recent Filing)$575.51M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Oct 23, 2025EPS Estimate
-1.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.70
Shares Outstanding211,374,790
10 Day Avg. Volume1,857,292
30 Day Avg. Volume2,750,200
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.59
Enterprise Value/Revenue45.06
Enterprise Value/Gross Profit59.76
Enterprise Value/Ebitda-19.19
Forecast
1Y Price Target
$156.24Price Target Upside7.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
Bulls Say, Bears Say
Bulls Say
Market PotentialCRSsNP represents a potentially significant market for brensocatib, with INSM estimating it could rival or even surpass the $5B NCFB opportunity.
Regulatory ApprovalBrensocatib was recently granted FDA approval for the treatment of non-cystic fibrosis bronchiectasis, paving the way for Insmed to embark on its largest launch yet.
Bears Say
Market Entry ChallengesThere is a belief that Insmed will not have the freedom to launch TPIP before 2034, which could impact its market entry timeline.
Symptom Improvement ConcernsThere is a lack of anecdotal evidence of nasal congestion and other symptom improvements in patients treated with Brensocatib, which is curious given the prevalence of CRS in NCFB patients.
Insmed News
INSM FAQ
What was Insmed’s price range in the past 12 months?
Insmed lowest stock price was $60.40 and its highest was $149.08 in the past 12 months.
What is Insmed’s market cap?
Insmed’s market cap is $30.60B.
When is Insmed’s upcoming earnings report date?
Insmed’s upcoming earnings report date is Oct 23, 2025 which is in 33 days.
How were Insmed’s earnings last quarter?
Insmed released its earnings results on Aug 07, 2025. The company reported -$1.7 earnings per share for the quarter, missing the consensus estimate of -$1.293 by -$0.407.
Is Insmed overvalued?
According to Wall Street analysts Insmed’s price is currently Undervalued.
Does Insmed pay dividends?
Insmed does not currently pay dividends.
What is Insmed’s EPS estimate?
Insmed’s EPS estimate is -1.34.
How many shares outstanding does Insmed have?
Insmed has 211,374,790 shares outstanding.
What happened to Insmed’s price movement after its last earnings report?
Insmed reported an EPS of -$1.7 in its last earnings report, missing expectations of -$1.293. Following the earnings report the stock price went down -1.762%.
Which hedge fund is a major shareholder of Insmed?
Currently, no hedge funds are holding shares in INSM
Insmed Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$156.24 (7.12% Upside)
$156.24 (7.12% Upside)
Blogger Sentiment
Bullish
INSM Sentiment 70%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Increased
By 3.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $8.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 2.1%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
100.16%
12-Months-Change
Fundamentals
Return on Equity
-160.54%
Trailing 12-Months
Asset Growth
37.00%
Trailing 12-Months
Company Description
Insmed
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with serious and rare diseases. The company primarily operates in the biotechnology sector, with a strong emphasis on developing treatments for conditions such as cystic fibrosis and pulmonary diseases. Insmed's core products include its lead product candidate, which targets rare respiratory conditions, enhancing the quality of life for affected patients.
INSM Company Deck
INSM Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Insmed's earnings call highlighted significant clinical and financial achievements, including successful late-stage clinical trials, a strong financial position, and impressive revenue growth. The company is well-prepared for the U.S. launch of brensocatib and has shown promising results from TPIP trials. However, challenges remain in the HS study and potential delays in BiRCh study data release. Overall, the positive developments outweigh the challenges.View all INSM earnings summariesINSM Stock 12 Month Forecast
Average Price Target
$156.24
▲(7.12% Upside)
Technical Analysis
Ownership Overview
0.93% Insiders
34.99% Mutual Funds
41.66% Other Institutional Investors
9.50% Public Companies and Individual Investors